Status:
COMPLETED
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare Symbicort with budesonide alone and with formoterol alone in the treatment of asthma in adolescents and adults
Eligibility Criteria
Inclusion
- At least 12 years of age
- Diagnosis of asthma
- Baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol
Exclusion
- Has required treatment with non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers
- Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2004
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00652002
Start Date
July 1 2002
End Date
January 1 2004
Last Update
January 24 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.